Risk of fungal infection in patients with psoriasis receiving biologics: A retrospective single-center cohort study
Authors:
- 30 September 2024
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (1) , 108-115
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trialsBritish Journal of Dermatology, 2023
- English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)The Journal of Dermatology, 2022
- Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infectionsJournal of Dermatological Science, 2021
- Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysisClinical Microbiology and Infection, 2020
- Chronic mucocutaneous candidiasis disease associated with inborn errors of IL‐17 immunityClinical & Translational Immunology, 2016
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisNew England Journal of Medicine, 2016
- Fungal Infections and New Biologic TherapiesCurrent Rheumatology Reports, 2016
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Fungal Infections Complicating Tumor Necrosis Factor α Blockade TherapyMayo Clinic Proceedings, 2008
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007